EMMANUEL MAKIA: Open Payments
NPI 1942866801 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$432 in 20 payments from 5 companies in 2025. Trend: 2023 $1,212 · 2024 $488 · 2025 $432
Food & beverage: $432
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $192 |
| Neurocrine BioSciences, Inc. | 5 | $155 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
| ACADIA Pharmaceuticals Inc | 1 | $18 |
Products named: REXULTI, INGREZZA, AUSTEDO XR, COBENFY, NUPLAZID.
Industry payments across TX — which companies pay providers there.
